Paclitaxel/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells.

Matrix metalloproteinases (MMPs) have been investigated as a potential target for treating invasive breast cancers. The chemotherapy for breast cancer is often prescribed as a combination of drugs. The present study investigates a novel strategy of combining a MMP inhibitor, Epigallocatechin gallate (EGCG), along with an anticancer drug, Paclitaxel (PTX), in the form of a liposomal co-delivery system.